Published in Exp Ther Med on January 01, 2010
Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res (2014) 0.88
Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis. Mol Clin Oncol (2015) 0.78
Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer. Cancer Sci (2016) 0.76
Circulating Cell-Free DNA Levels Could Predict Oncological Outcomes of Patients Undergoing Esophagectomy for Esophageal Squamous Cell Carcinoma. Int J Mol Sci (2016) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 16.92
Esophageal cancer. N Engl J Med (2003) 15.23
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol (2003) 2.31
Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer (1996) 1.82
Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol (2006) 1.73
Chemoradiation in the management of esophageal cancer. J Clin Oncol (2007) 1.68
Clinical utility of cytokeratins as tumor markers. Clin Biochem (2004) 1.63
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol (2004) 1.57
Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg (2006) 1.31
Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res (1996) 1.28
CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer (1997) 1.06
Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res (2007) 0.97
CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res (2000) 0.92
Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res (2007) 0.88
The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma. Br J Cancer (1999) 0.87
Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer (2007) 0.87
Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma. Oncol Rep (2008) 0.86
Abdominal lymph node metastasis in patients with mid thoracic esophageal squamous cell carcinoma. World J Surg (2009) 0.85
Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet (2003) 3.93
Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med (2007) 1.75
Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res (2002) 1.64
Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg (2012) 1.47
A new type of protein chip to detect hepatocellular carcinoma-related autoimmune antibodies in the sera of hepatitis C virus-positive patients. Proteome Sci (2013) 1.44
Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia (2008) 1.28
Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol (2008) 1.26
Simple genotype analysis of the Asp299Gly polymorphism of the Toll-like receptor-4 gene that is associated with lipopolysaccharide hyporesponsiveness. J Clin Lab Anal (2002) 1.23
Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg (2010) 1.22
Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol (2007) 1.22
Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics (2005) 1.20
Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma. FEBS Lett (2003) 1.15
Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol (2004) 1.15
Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer (2009) 1.14
Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer (2002) 1.12
TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer (2010) 1.10
Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer. Cancer Lett (2002) 1.10
Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics (2003) 1.07
Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol (2003) 1.06
Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. Clin Cancer Res (2008) 1.05
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04
Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res (2008) 1.04
Integrin alpha2 mediates selective metastasis to the liver. Cancer Res (2009) 1.03
Sentinel lymph node biopsy using computed tomography-lymphography in patients with breast cancer. Surgery (2004) 1.03
Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer (2002) 1.02
Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics (2004) 1.00
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med (2014) 0.99
Impact of surgical site infection after colorectal surgery on hospital stay and medical expenditure in Japan. Surg Today (2012) 0.99
Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res (2002) 0.98
Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics (2006) 0.98
Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping. World J Surg (2007) 0.98
Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis. Oncogene (2003) 0.97
MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res (2005) 0.96
Breast sentinel lymph node mapping at CT lymphography with iopamidol: preliminary experience. Radiology (2003) 0.96
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Res Notes (2012) 0.96
Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol (2005) 0.96
Lymphatic drainage from esophagogastric tract: feasibility of endoscopic CT lymphography for direct visualization of pathways. Radiology (2005) 0.96
A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med (2014) 0.96
Predicting individual outcomes in hepatocellular carcinoma. Lancet (2004) 0.95
Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci (2009) 0.95
Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res (2012) 0.94
Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics (2005) 0.93
Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Sci (2008) 0.92
Gain of 5p15 detected by comparative genomic hybridization as an independent marker of poor prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res (2002) 0.92
A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother (2014) 0.92
Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer (2002) 0.92
Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis. Cancer Genet Cytogenet (2003) 0.92
A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study. J Pathol (2009) 0.92
Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells. Oncogene (2002) 0.92
Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res (2009) 0.92
Protocol and standard operating procedures for common use in a worldwide multicenter study on reference values. Clin Chem Lab Med (2013) 0.91
Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer (2005) 0.91
Imbalance in expression levels of insulin-like growth factor 2 and H19 transcripts linked to progression of hepatocellular carcinoma. Anticancer Res (2005) 0.91
The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. Jpn J Clin Oncol (2010) 0.90
A multicenter nationwide reference intervals study for common biochemical analytes in Turkey using Abbott analyzers. Clin Chem Lab Med (2014) 0.90
The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg (2009) 0.90
Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. J Hepatobiliary Pancreat Sci (2015) 0.90
Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search. Int J Oncol (2008) 0.89
Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy. Oncol Rep (2006) 0.89
Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol (2006) 0.89
Photon pair generation in a silicon micro-ring resonator with reverse bias enhancement. Opt Express (2013) 0.89
High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology (2009) 0.89
Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer (2014) 0.89
Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep (2008) 0.89
Molecular signature in three types of hepatocellular carcinoma with different viral origin by oligonucleotide microarray. Int J Oncol (2004) 0.88
Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res (2007) 0.88
CT lymphography-navigated sentinel lymph node biopsy in patients with superficial esophageal cancer. Surgery (2006) 0.88
Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J Transl Med (2014) 0.88
Identification of common or distinct genes related to antitumor activities of a medicinal herb and its major component by oligonucleotide microarray. Int J Cancer (2003) 0.88